Quoin Pharmaceuticals Provides Clinical And Regulatory Update From Constructive Type C Meeting With U.S. FDA For Qrx003 In Netherton Syndrome

Quoin Pharmaceuticals Ltd 2EB0y.F:

• QUOIN PHARMACEUTICALS PROVIDES CLINICAL AND REGULATORY UPDATE FROM CONSTRUCTIVE TYPE C MEETING WITH U.S. FDA FOR QRX003 IN NETHERTON SYNDROME

• QUOIN PHARMACEUTICALS LTD - FDA OPEN TO ALTERNATIVE PHASE 3 DESIGN FOR QRX003 WITHOUT TRADITIONAL PLACEBO CONTROL

• QUOIN PHARMACEUTICALS LTD - FDA INDICATES SINGLE PHASE 3 STUDY MAY BE SUFFICIENT FOR QRX003 U.S. APPROVAL

• QUOIN PHARMACEUTICALS LTD - ON TRACK TO COMPLETE PHASE 3 RECRUITMENT IN 2026, FILE NDA IN 2027

• QUOIN PHARMACEUTICALS LTD - TO SUBMIT PHASE 2 AND PEDIATRIC DATA, REQUEST FDA MEETING BEFORE PHASE 3 QRX003

Further company coverage: [2EB0y.F]